Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Pilot Study for Assessing the Safety and Efficacy of High-Dose Ambroxol (HDA) in Newly Diagnosed GBA1 Parkinson Disease (PD)

NCT06193421 is registered in ClinicalTrials.gov with Agyany Pharma LTD as lead sponsor.

NCT NCT06193421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06193421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Pilot Study for Assessing the Safety and Efficacy of High-Dose Ambroxol (HDA) in Newly Diagnosed GBA1 Parkinson Disease (PD)
Lead sponsor
Agyany Pharma LTD
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 24, 2023
Completion date
April 30, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gba gene mutation, parkinson disease